Identification
- Summary
Peginterferon alfa-2b is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers.
- Brand Names
- Pegintron, Sylatron
- Generic Name
- Peginterferon alfa-2b
- DrugBank Accession Number
- DB00022
- Background
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients 3. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2b is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2b has largely declined since newer interferon-free antiviral therapies have been developed.
In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2b for the treatment of Hepatitis C 2. Peginterferon alfa-2b was used alongside Ribavirin(https://go.drugbank.com/drugs/DB00811) with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality 1.
Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron) used for the treatment of chronic Hepatitis C. Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with Ribavirin or other antiviral drugs Label. When combined together, Peginterferon alfa-2b and Ribavirin have been shown to achieve a SVR between 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Interferons - Protein Structure
- Protein Chemical Formula
- Not Available
- Protein Average Weight
- 31000.0 Da
- Sequences
>DB00022 sequence CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Download FASTA Format- Synonyms
- Peginterferon alfa-2b
Pharmacology
- Indication
Peginterferon alfa-2b is indicated for the treatment of HCV in combination with Ribavirin and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 Label. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
It is also indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection, including complete lymphadenectomy.4
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Chronic hepatitis c virus (hcv) infection •••••••••••• ••••• •••••••••• ••••••••• ••••••••• Treatment of Chronic hepatitis c virus (hcv) infection •••••••••••• ••••••••••• ••••• •••••••• •••••••• ••• •••• ••••••••• •• ••••••••••••••• ••••••••• Used in combination to treat Chronic hepatitis c virus (hcv) infection Regimen in combination with: Ribavirin (DB00811) •••••••••••• ••••••••••• ••••••••• ••••••••• Used in combination to treat Chronic hepatitis c virus (hcv) infection Regimen in combination with: Ribavirin (DB00811) •••••••••••• ••••• ••••••••• Used in combination to treat Chronic hepatitis c virus (hcv) infection Regimen in combination with: Ribavirin (DB00811) •••••••••••• ••••• ••• •••••••• • ••••••••• ••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Peginterferon alfa-2b inhibits viral replication in infected cells, suppresses cell proliferation, induces apoptosis, and exerts an anti-angiogenic effect Label. Exerts immunomodulatory effects such as enhancement of the phagocytic activity of macrophages, activation of NK cells, stimulation of cytotoxic T-lymphocytes, and the upregulation of the Th1 T-helper cell subset. Also increases concentrations of effector proteins such as serum neopterin and 2'5' oligoadenylate synthetase, raises body temperature, and causes reversible decreases in leukocyte and platelet counts.
- Mechanism of action
Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity Label. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response. Peginterferon alfa-2b may also acitvate the nuclear factor κB pathway.
Target Actions Organism AInterferon alpha/beta receptor 1 agonistHumans AInterferon alpha/beta receptor 2 agonistHumans - Absorption
Peginterferon alfa-2b reaches peak plasma concentration 15-44 hours after subcutaneous administration Label. The mean absorption half-life is 4.6 hours. After multiple doses the bioavailability of Peginterferon alfa-2b increases with trough concentrations at week 48 3-fold higher than those at week 4.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Renal elimination accounts for 30% of Peginterferon alfa-2b elimination Label.
- Half-life
The mean half-life of elimination of Peginterferon alfa-2b is 40 hours in a range of 22-60 hours Label.
- Clearance
The estimated apparent clearance of Peginterferon alfa-2b is 22 milliters per hour per kilogram Label.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Peginterferon alfa-2b may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose Label. Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction have been observed in patients using Peginterferon alfa-2b. Peginterferon alfa-2b may produce myelosuppression as well as the development or aggravation of autoimmune disorders including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus. Peginterferon alfa-2b causes or aggravates hypothyroidism and hyperthyroidism. Hyperglycemia, hypoglycemia, and diabetes mellitus have been observed to develop in patients treated with Peginterferon alfa-2b. Peginterferon alfa-2b may decrease or produce loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema and serous retinal detachment. Peginterferon mayy be related to increased ischemic and hemorrhagic cerebrovascular events. Patients with cirrhosis on Peginterferon alfa-2b are at risk of hepatic decompensation. Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension and sarcoidosis may be induced or aggravated by Peginterferon alfa-2b. Serious and severe infections (bacterial, viral, or fungal) have been reported during treatment with Peginterferon alfa-2b. Ulcerative and hemorrhagic/ischemic colitis have been observed within 12 weeks of starting Peginterferon alfa-2b treatment. Pancreatitis and peripheral nephropathy have also been reported. Peginterferon alfa-2b is associated with growth inhibition in pediatric patients. Use of Peginterferon alfa-2b while pregant may result in delopmental abnormalities or death of the fetus.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Interferon lambda-3 --- (T;T) / (C;T) / (G;G) / (G;T) C > T Effect Directly Studied Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2b therapy. Details
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Peginterferon alfa-2b. Abrocitinib The metabolism of Abrocitinib can be increased when combined with Peginterferon alfa-2b. Acebutolol The metabolism of Acebutolol can be decreased when combined with Peginterferon alfa-2b. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b. - Food Interactions
- Limit caffeine intake. Peginterferon alfa-2b can increase the serum levels of caffeine by inhibiting its metabolism through the CYP1A2 pathway.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Interferon alfa-2b unknown 43K1W2T1M6 98530-12-2 Not applicable - International/Other Brands
- PEG-Intron (Schering Corp)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Pegintron Injection, powder, for solution 80 mcg Subcutaneous Merck Sharp & Dohme B.V. 2021-02-11 2021-06-03 EU 
Pegintron Kit 120 ug/0.5mL Subcutaneous Merck Sharp & Dohme Limited 2001-01-19 2016-03-06 US 
Pegintron Injection, powder, for solution 100 mcg Subcutaneous Merck Sharp & Dohme B.V. 2021-02-11 2021-06-03 EU Pegintron Injection, powder, for solution 50 mcg Subcutaneous Merck Sharp & Dohme B.V. 2021-02-11 2021-06-03 EU Pegintron Injection, powder, for solution 80 mcg Subcutaneous Merck Sharp & Dohme B.V. 2021-02-11 2021-06-03 EU - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Pegetron Peginterferon alfa-2b (120 mcg / 0.5 mL) + Ribavirin (200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2002-08-13 2013-01-23 Canada 
Pegetron Peginterferon alfa-2b (120 mcg / 0.5 mL) + Ribavirin (200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2004-09-17 2017-10-05 Canada Pegetron Peginterferon alfa-2b (150 mcg / 0.5 mL) + Ribavirin (200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2002-08-13 2017-04-04 Canada Pegetron Peginterferon alfa-2b (100 mcg / 0.5 mL) + Ribavirin (200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2002-08-13 2013-01-23 Canada Pegetron Peginterferon alfa-2b (100 mcg / 0.5 mL) + Ribavirin (200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2004-09-17 2017-10-05 Canada
Categories
- ATC Codes
- L03AB10 — Peginterferon alfa-2b
- L03AB — Interferons
- L03A — IMMUNOSTIMULANTS
- L03 — IMMUNOSTIMULANTS
- L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- Drug Categories
- Adjuvants, Immunologic
- Alcohols
- Alfa Interferons
- Amino Acids, Peptides, and Proteins
- Anti-Infective Agents
- Antineoplastic and Immunomodulating Agents
- Antiviral Agents
- Biological Factors
- Cancer immunotherapy
- Compounds used in a research, industrial, or household setting
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)
- Cytochrome P-450 CYP2C9 Inducers
- Cytochrome P-450 CYP2C9 Inducers (weak)
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Cytokines
- Drug Carriers
- Ethylene Glycols
- Glycols
- Hepatitis C
- Immunosuppressive Agents
- Immunotherapy
- Intercellular Signaling Peptides and Proteins
- Interferon alpha
- Interferon Type I
- Interferon-alpha
- Interferons
- Macromolecular Substances
- Myelosuppressive Agents
- Pegylated agents
- Peptides
- Polymers
- Proteins
- Treatments for Hepatitis C
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- G8RGG88B68
- CAS number
- 215647-85-1
References
- General References
- Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [Article]
- Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [Article]
- American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
- FDA Approved Drug Products: SYLATRON (peginterferon alfa-2b) for injection, for subcutaneous use (December 2018) [Link]
- External Links
- UniProt
- P01563
- PubChem Substance
- 46506669
- 253453
- ChEMBL
- CHEMBL1201561
- Therapeutic Targets Database
- DAP001279
- PharmGKB
- PA164784024
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Peginterferon_alfa-2b
- FDA label
- Download (1.69 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Advanced Fibrosis / Cirrhosis of the Liver / Hepatitis C Virus (HCV) Infection 1 4 Completed Treatment Antiviral Agents / Chronic Liver Disease / Hepatitis C Virus (HCV) Infection / Therapeutic Uses / Virus Hepatitis 1 4 Completed Treatment Chronic Hepatitis B Infection 1 4 Completed Treatment Chronic Hepatitis C Virus (HCV) Infection 5 4 Completed Treatment Hepatitis C Infections / Human Immunodeficiency Virus (HIV) Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Physicians Total Care Inc.
- Schering Corp.
- Schering-Plough Inc.
- Vetter Pharma Fertigung GmbH and Co. KG
- Dosage Forms
Form Route Strength Injection, powder, for solution Subcutaneous 100 mcg/0.5ml Injection, powder, for solution Subcutaneous 120 mcg/0.5ml Injection, powder, for solution Subcutaneous 150 mcg/0.5ml Injection, powder, for solution Subcutaneous 50 mcg/0.5ml Injection, powder, for solution Subcutaneous 80 mcg/0.5ml Capsule; powder, for solution Oral; Subcutaneous Injection, powder, for solution; kit Subcutaneous 120 ug/0.5mL Injection, powder, for solution; kit Subcutaneous 150 ug/0.5mL Injection, powder, for solution; kit Subcutaneous 50 ug/0.5mL Injection, powder, for solution; kit Subcutaneous 80 ug/0.5mL Injection, powder, lyophilized, for solution Subcutaneous 120 ug/0.5mL Injection, powder, lyophilized, for solution Subcutaneous 150 ug/0.5mL Injection, powder, lyophilized, for solution Subcutaneous 50 ug/0.5mL Injection, powder, lyophilized, for solution Subcutaneous 80 ug/0.5mL Kit Subcutaneous 120 ug/0.5mL Kit Subcutaneous 150 ug/0.5mL Kit Subcutaneous 50 ug/0.5mL Kit Subcutaneous 80 ug/0.5mL Injection, solution 100 mcg Injection, solution 120 mcg Injection, solution 150 mcg Injection, solution 50 mcg Injection, solution 80 mcg Injection, powder, lyophilized, for solution Subcutaneous 50 mcg Kit Subcutaneous 120 ug/0.1mL Kit Subcutaneous 40 ug/0.1mL Kit Subcutaneous 60 ug/0.1mL Powder, for solution Subcutaneous 118.4 mcg / vial Powder, for solution Subcutaneous 177.6 mcg / vial Powder, for solution Subcutaneous 222 mcg / vial Powder, for solution Subcutaneous 74 mcg / vial Injection, powder, for solution Subcutaneous 100 MCG Injection, powder, for solution Subcutaneous 120 MCG Injection, powder, for solution Subcutaneous 150 MCG Injection, powder, for solution Subcutaneous 50 MCG Injection, powder, for solution Subcutaneous 80 MCG Powder 100 mcg/1vial - Prices
Unit description Cost Unit Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box 2428.8USD kit Peg-Intron Redipen 150 mcg/0.5ml Kit 702.87USD kit Peg-Intron 150 mcg Kit 671.74USD kit Peg-Intron Redipen 120 mcg/0.5ml Kit 669.39USD kit Peg-Intron redipen 150 mcg 640.61USD redipen Peg-Intron redipen 150 mcg 4pk 640.6USD redipen Peg-Intron 120 mcg Kit 639.74USD kit Peg-Intron Redipen 80 mcg/0.5ml Kit 637.49USD kit Peg-Intron redipen 120 mcg 610.09USD redipen Peg-Intron 80 mcg Kit 609.26USD kit Peg-Intron 50 mcg/0.5ml Kit 607.19USD kit Peg-Intron redipen 80 mcg 581.02USD redipen Peg-Intron 50 mcg kit 553.4USD kit Peg-Intron redipen 50 mcg 553.4USD redipen DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA1341567 No 2008-02-19 2025-02-19 Canada CA2329474 No 2002-02-26 2016-10-31 Canada
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 61 °C Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999) isoelectric point 5.99 Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Type i interferon receptor activity
- Specific Function
- Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JA...
- Gene Name
- IFNAR1
- Uniprot ID
- P17181
- Uniprot Name
- Interferon alpha/beta receptor 1
- Molecular Weight
- 63524.81 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [Article]
- Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [Article]
- Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Type i interferon receptor activity
- Specific Function
- Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are direc...
- Gene Name
- IFNAR2
- Uniprot ID
- P48551
- Uniprot Name
- Interferon alpha/beta receptor 2
- Molecular Weight
- 57758.24 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [Article]
- Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [Article]
- Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- Curator comments
- The FDA label states that single doses of this agent may not affect the CYP1A2 enzyme, however, the effect of multiple doses has not been studied.
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Gupta SK, Kolz K, Cutler DL: Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol. 2011 Jun;67(6):591-9. doi: 10.1007/s00228-010-0972-5. Epub 2010 Dec 16. [Article]
- Peg-interferon alfa-2b FDA label [File]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:54